(20S) -Protopanaxatriol

(20S) -Protopanaxatriol is a metabolite of ginsenoside. (20S) -Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a LXRα inhibitor. (20S) -Protopanaxatriol shows a broad spectrum of antitumor effects[1][2][3].

Product Specifications

CAS Number

[34080-08-5]

Product Name Alternative

20 (S) -APPT; g-PPT

UNSPSC

12352211

Target

Apoptosis; Estrogen Receptor/ERR; Glucocorticoid Receptor; LXR

Type

Natural Products

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Endocrinology; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/_20S_-Protopanaxatriol.html

Purity

99.93

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O)[C@@]2([H])C3(C)C)[C@]4([C@@]1([H])[C@]([C@@](C)(O)CC/C=C(C)/C)([H])CC4)C

Molecular Formula

C30H52O4

Molecular Weight

476.73

References & Citations

[1]Leung KW, et al. Protopanaxadiol and protopanaxatriol bind to glucocorticoid and oestrogen receptors in endothelial cells. Br J Pharmacol. 2009 Feb;156 (4) :626-37.|[2]Oh GS, et al. 20 (S) -protopanaxatriol inhibits liver X receptor α-mediated expression of lipogenic genes in hepatocytes. J Pharmacol Sci. 2015 Jun;128 (2) :71-7.|[3]Huang Q, et al. Co-administration of 20 (S) -protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38 (1) :129. Published 2019 Mar 15.|[4]Zhang H, et al. 20 (S) -Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway. Int J Mol Sci. 2018;19 (4) :1053. Published 2018 Apr 2.